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Abstract
Objective
We aimed to investigate the clinical and para clinical manifestations of neuro 
metabolic disorders, in patients who presented by neuro developmental delay in 
their neuro developmental milestones.
Materials & Methods
The patients diagnosed as neuro developmental delay and regression with or 
without seizure at the Neurology Department of Mofid Children Hospital in 
Tehran, Iran between 2004 and 2014 were included in our study. These patients 
diagnosed as neuro developmental delay by pediatric neurologists in view of 
diagnostic /screening neuro developmental assessment tests. The patients who 
completed our inclusion criteria as neuro metabolic disorders were evaluated in 
terms of metabolic and genetic study in referral lab.
Results
Overall, 213 patients with neurometabolic disorders were diagnosed. 54.3% of 
patients were male. The average age of patients was 41 +-46.1 months. 71.4% 
of parent’s patients had consanguinity of marriages. Eighty seven percent of 
patients had developmental delay (or/and) regression. 55.5% of them had 
different type of seizures. Overall, 213 patients with 34 different neurometabolic 
disorders were diagnosed and classified in the 7 sub classes, consisting of: 
1- organic acidemia and aminoacidopathy (122 patients), 2-storage disease 
(37 patients) 3- eukodystrophy (27 patients), other classes consisted: lipid 
oxidation disorders, urea cycle disorders, progressive myoclonic epilepsy; and 
peroxizomal disorders (27 patients).
Conclusion
In patients with developmental delay or regression, with or without seizure, 
abnormal neurologic exam along with positive family history of similar disorder 
or relative parents, abnormal brain imaging with specific patterns, neurometabolic 
disorders should be considered as one of the important treatable diseases 
Keywords: Clinical findings; Neurometabolic disorders; Children; 
Developmental delay; Seizure
Introduction
The incidence of autosomal recessive neurometabolic disorders is relatively high in 
Iran, probably due to the frequency of consanguineous marriages. Reevaluation of 
patients with delayed neuro developmental milestones in a referral neurometabolic 
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or myelination delay), brain edema, brain atrophy 
(generalized; cortical atrophy; cerebellum atrophy; or 
sylvan groove opening due to fronto temporal atrophy), 
hemorrhage (parenchymal hemorrhage, subdural 
hematoma, or stroke), basal ganglia involvement 
(globus pallidus, putamen, caudate nucleus), thalamus, 
cyst, subdural effusion, axial hydrocephaly, heterotopia, 
cortical malformation, MRS involvement, and corpus 
callosum agenesia were assessed.
Institutional ethical approval was obtained from the 
Pediatric Neurology Research Center of Shahid Beheshti 
University of Medical Sciences, Tehran, Iran. All parents 
signed a written consent for participation in this study.
The data were analyzed using SPSS (Chicago, IL, USA).
Results
Overall, 213 patients with 34 different neurometabolic 
disorders were diagnosed. A total of 54.3% were male. 
The median age of patients at detection time was 41 +- 
46.1 months (Figure 1). A total of 23.5% of patients had 
a positive family history of similar diseases. 71.4% of 
patients were offspring of consanguineous marriages as 
follows: 57.4% were first degree and 14% were second 
degree. 
Patients were classified in 7 classes as follows: 1- 
organic acidemia and aminoacidopathy in 122 patients 
that 15.6% had normal development, 9.8% regression, 
54.1% developmental delay, 20.5% developmental 
delay plus regression, 2-storage disease in 37 patients 
(10.8% of these patients had normal development, 
32.4% regression, 32.4% developmental delay, 24.3% 
developmental delay plus regression 3- leukodystrophy 
in 27 patients (3.7% of these patients had normal 
development, 29.6% regression, 33.3% developmental 
delay, 33.3% developmental delay plus regression), 
other classes consisted of lipid oxidation disorders, 
urea cycle disorders, progressive myoclonic epilepsy; 
peroxizomal disorders in 27 patients (4 patients had 
normal development, 7 patients had regression, 14 of 
these patients had developmental delay and two people 
had developmental delay plus regression.
  
center is very important. Early detection and early 
intervention of patients with neuro developmental 
delay/ regression as treatable neuro metabolic disorder 
can cause prevention of more brain insults during early 
infants and childhood.
There are few beneficial clinical criteria for differentiating 
neuro metabolic disorders (2, 3). Most of the time, the 
presenting symptoms are nonspecific (4-6). Morbidity 
and mortality is the main result of neurodegenerative 
and neuro metabolic disorders in children. 
In this study we report complete practical criteria on 
children with developmental delay/regression with 
or without seizure as neuro metabolic cases referred 
to the Pediatric Neurology Research Center of Mofid 
Children’s Hospital, Tehran, Iran. 
Materials & Methods
This diagnostic study was performed on patients referred 
to the Neurology Department of Mofid Children’s 
Hospital in Tehran, Iran with neuro developmental 
delay and regression with or without seizure or other 
items that predisposed them to metabolic disease. The 
diagnosis was done based on clinical manifestation, 
laboratory assessment and neuro imaging findings. The 
demographic data of patients were gathered as age, 
gender, developmental status, past medical history, and 
clinical and neuro imaging findings.
We applied practical criteria for our patients in view 
of elementary diagnosis and then evaluated them by 
metabolic /genetic study for confirming of our diagnosis.
The neuro metabolic disorders diagnosis was confirmed 
based on the type of disorder including acylcarnitine 
profile assessment in lipid oxidation disorders; 
enzyme assessment in Sandhoff and Tay–Sachs 
disease; biotinidase deficiency (BD); metachromatic 
leukodystrophy (MLD) and galactosemia; very long 
chain fatty acid (VLCFA) assessment in peroxisomal 
disorders; serum acyl carnitine profile assessment and 
urine organic acid in organic acidemia; and genetic 
assessment in plezeous merzbacher disease (PMD), 
PMD-like and for confirmation of other neurometabolic 
disorders. In the radiological assessment, location and 
pattern of white matter involvement (pre-ventricular 
involvement with anterior or posterior dominancy, with 
or without u-fiber involvement, leukodystrophic pattern 
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Totally, in developmental assessment 87% of patients 
showed neuro developmental delay/regression (consisted 
of 47.4% developmental delays; 21.1% developmental 
delays and regression and 18.3% developmental 
regression.) and only 13% of patients had normal 
development. Normal developmental status was seen in 
girls more than boys (Risk estimate: odds ratio for sex 
(female/male)=1.57). Normal developmental status was 
seen more on MCAD (8 patients) and homocystinuria (7 
patients) disorders. Abnormal EEG was seen in 10.7% 
patients with normal development and 22.3% of patients 
with abnormal development (Odds ratio for EEG finding 
(NL/Abnormal) =2.38 with confidence interval 95%. 
MRI showed normal pattern in 10.7% of patients with 
normal development and 30% of patients with abnormal 
developmental status. Behavioral disorder was detected 
in 16.9% of patients. 
On examination, positive points in order of frequency 
consisted of: Abnormal muscular tonicity in 49.8% of 
patients, and ophthalmological problems in 32.9% of 
patients. Decreased level of consciousness episodes was 
seen in 5.2% etc. (Table1). A total of 16% of patients 
were microcephaly and 12.7% were macrocephaly. A 
total of 55.5% of patients had seizures, of which the 
most common type was tonic and then GTC. Auditory 
problems were seen in 6.6% of patients.
Positive points in paraclinical assessments in patients in 
order of frequency consisted of: increased ammonia and 
lactate increased liver enzymes, etc. (Table 1).
Table 1. Positive Para Clinical Findings in Our Patients 
in This Study.
 % n
 18.3 39 High Lactate
 13.6 29 High Ammonia
 11.3 24 High Liver enzymes
 10.8 23 Anemia
 10.3 22 Acidosis
 7.0 15 Abnormal HpLC
 0.9 2 Low BS
 0.5 1 High CSF/Pro
 0.5 1 Low Calcium
Fig1. Distribution of patient’s age in our study 
 
Figure ١: Distribution of patient's age in our study  
 
Totally, in developmental assessment ٨٧% of patients showed neuro developmental 
delay/regression (consisted of ٤٧.٤% developmental delays; ٢١.١% developmental delays and 
regression and ١٨.٣% developmental regression.) and only ١٣٪ of patients had normal 
development. Normal developmental status was seen in girls more than boys (Risk estimate: 
Mean ± SD: 41 ± 46.1
Min: 0.5
Max: 276
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Brain imaging in 36% of patients was normal; 20.4% 
of patients had brain atrophy; 25.1% had white matter 
involvement; 4.3% had basal ganglia involvement; 2.8% 
had basal ganglia and white matter involvement; 2.4% 
had basal ganglia involvement and brain atrophy. Brain 
atrophy with white matter involvement was seen in 5.7% 
of patients.
In patients with organic acidemia and aminoacidopathy 
(including methyl malonic acidemia, Propionic 
acidemia, isovaleric acidemia, glutaricaciduria I and II, 
MSUD, NKH, tyrosinemia, galactosemia, biotinidase 
deficiency, PKU, hemocysteinuria and MTHFR); in 
33% of patients, brain imaging was normal; 28.9% of 
patients had brain atrophy; 24.5% of patients had white 
matter involvement; the rest of patients had basal ganglia 
along with other area involvement.
For example, among 22 patients with glutaric aciduria, 20 
patients had brain atrophy especially in fronto temporal 
regions with sylvian groove widening (Figure 2); 6 
patients had white matter involvement and 6 patients had 
basal ganglia involvement.
In 32 patients with PKU, 17 had white matter 
involvement and 6 patients had brain atrophy plus white 
matter involvement.
For example, among ٢٢ patients with glutaric aciduria, ٢٠ patients had brain atrophy 
especially in fronto temporal regions with sylvian groove widening (Figure ٢); ٦ patients 
had white matter involvement and ٦ patients had basal ganglia involvement. 
In ٣٢ patients with PKU, ١٧ had white matter involvement and ٦ patients had brain atrophy 
plus white matter involvement. 
 
 
 
Figure ٢: A ٦-month-old boy-with Glutaric aciduria type١ with sylvian fissure widening in axial brain 
MRI 
 
In patients with storage disorders (including Gaucher's, Niemann pick, GSD, Sandhoff and 
Tay–Sachs disease and Wilson’s disease); ٥٥.٦٪ had normal brain MRI; ١١٪ had brain 
Fig 2. A 6-month-old boy-with Glutaric aciduria type1 
with sylvian fissure widening in axial brain MRI
In patients with storage disorders (including Gaucher’s, 
Niemann pick, GSD, Sandhoff and Tay–Sachs disease 
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and Wilson’s disease); 55.6% had normal brain 
MRI; 11% had brain atrophy; 11% had white matter 
involvement; 8.3% had basal ganglia involvement 
and the remaining of patients had involvement in 
different regions. For example, 18 patients had GM2 
gangliosidosis (Sandhoff and Tay–Sachs disease) that 
bilateral thalamus involvement in 5 patients; generalized 
brain atrophy in 5 patients; and white matter involvement 
as myelination delay in 3 patients were seen. 
In patients with urea cycle disorders, 33.3% had brain 
atrophy and 66.7% had white matter involvement.
22.2% of patients with peroxisomal disorders including 
ALD and Zellweger syndrome had normal brain MRI; 
55.6% had white matter involvement; 11% had structural 
disorder and 11% had subdural hematoma.
72.7% of patients with fatty acid oxidation disorders 
including medium chain acyl coa deficiency (MCAD), 
long chain acyl coa deficiency (LCAD), short chain acyl 
coa deficiency (SCAD), and multiple carboxylase had 
normal brain MRI; 18.2% had brain atrophy, and 9% 
had basal ganglia involvement.
In leukodystrophic disorders including MLD, Krabbe 
disease, Canavan, PMD, PMD-like; 7.4% of patients 
had normal imaging; 3.7% had brain atrophy; 81.5% 
had white matter involvement (Figure 3); 3.7% had 
basal gangliaand white matter involvement and 3.7% 
had white matter involvement and brain atrophy. 
 
 
Figure ٣- An ٨-yr old-girl with metacromatic leuckodystrophia with periventricular white matter 
involvement (Butter-fly pattern) in imaging 
 
For example, all the patients with Canavan disease (١٧ patients) had extensive white matter 
and u-fiber involvement, one patient had subdural effusion. From ٤ patients with MLD, all 
of patients had white matter involvement as leukodystrophy with bilateral periventricular 
involvement without u-fiber involvement. 
 
Thirty six percent of patients with progressive myoclonic epilepsy (including NCL١, NCL٢, 
Melas disease and Leigh disease), had normal imaging; ٢٠.٤٪ of patients had brain atrophy; 
٢٥.١٪ had white matter involvement, and the rest of patients had involvement in different 
regions. 
 
MRS was done in some of these patients, consisting of ١٧ patients with canavan disorder 
(that showed elevated level of N-acetyl aspartic acid), ٣ patients with mitochondrial disorder 
(that showed elevated level of lactate), ٤ patients with leukodystrophy in Brain MRI (that 
showed elevated level of choline/NAA ratio). 
 
Fig 3. An 8-yr old-girl with metacromatic 
leuckodystrophia with periventricular white matter 
involvement (Butter-fly pattern) in imaging
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disorders with different diagnostic method in referral 
lab (such as enzyme study, acylcarnitine profile, 
genetic study etc.).
Out of 213 patients, 122 had organic acidemia and 
aminoacidopathy, 37 had storage disease, 27 had 
leukodystrophy, 27 had lipid oxidation disorders, 
urea cycle disorders, and progressive myoclonic 
epilepsy or peroxizomal disorders. Therefor the result 
of neuromrtabolic assessments as mention above, 
confirmed our practical criteria.
Discussion
71.4% of parents of our patients were relative (71.4%) 
and 23.5% of patients had positive family history of 
similar metabolic disordes. that in the other articles, the 
same results were noted. For example total of patients 
with MLC had history of consanguinity of marriage (7). 
Besides, 75% of 24 patients with hereditary metabolic 
disordes had history of consanguinity of marriage in 
their parents, and positive family history of similar 
metabolic disordes in 34% of first-degree relative (8).
Seizures are one of the important presentations in 
neurometabolic disordes. 36.5% % of our patients 
presented with seizure. Cause of 7% of neonatal 
seizures was metabolic disorders (9). Because metabolic 
disordes often involved the brain, there for, epilepsy 
same as other neurologic manifestations is common in 
these diseases (10). Assessment on 220 children with 
epilepsy in the first two years of life appeared and in 24 
of these cases the etiology of seizures was metabolic 
disorders (8).
Eight seven pecent of our patients illustrated 
developmental delay or developmental regression. 
Neurometabolic disorders can present with 
developmental delay and regression and the symptoms 
can appear at any age from newborns into adulthood 
(11).
Developmental delay is a major symptom of various 
metabolic disorders that appear at the young age. 
So, understanding the general characteristics of 
developmental delay caused by metabolic disorders is 
an essential step for better identification and appropriate 
follow-up with metabolic workup (12).
Bilateral thalamus involvement in patients (Turkish 
mustache pattern) and brain atrophy were seen in our 
For example, all the patients with Canavan disease 
(17 patients) had extensive white matter and u-fiber 
involvement, one patient had subdural effusion. 
From 4 patients with MLD, all of patients had 
white matter involvement as leukodystrophy with 
bilateral periventricular involvement without u-fiber 
involvement.
Thirty six percent of patients with progressive 
myoclonic epilepsy (including NCL1, NCL2, Melas 
disease and Leigh disease), had normal imaging; 20.4% 
of patients had brain atrophy; 25.1% had white matter 
involvement, and the rest of patients had involvement 
in different regions.
MRS was done in some of these patients, consisting 
of 17 patients with canavan disorder (that showed 
elevated level of N-acetyl aspartic acid), 3 patients with 
mitochondrial disorder (that showed elevated level of 
lactate), 4 patients with leukodystrophy in Brain MRI 
(that showed elevated level of choline/NAA ratio).
 
Fig 4. A 13-yr-old girl with wilson disease that 
showed basal ganglia involvement in brain imaging
Finally, patients who were fulfilled a number of 
our practical criteria items consisting (Table 2): 
Consanguinity of marriage, history of the same disorder 
or death in sibling, abnormal nurological exam, specific 
clinical findings, abnormal developmental status, 
seizure, abnormal EEG and abnormal brain imaging 
with specific patterns, were assessed as neurometabolic 
Neurometabolic Diagnosis in Children who referred as Neurodevelopmental Delay...
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patients with GM2 gangliosides (Sandhoff disease and 
Tay-Sachs disease). Brain MRI in patients with GM2 
gangliosides show white matter abnormalities and 
changes in myelination of white matter that may be due 
to neuronal damage (13, 14).
Our patients with glutaric aciduria had fronto temporal 
atrophy and sylvan fissure widening. Sylvan fissure 
widening and abnormalities in the basal ganglia, atrophy, 
and leukoencephalopathy has been reported in glutaric 
aciduria type 1 (15, 16).
We found heterotopia and cortical malformation in our 
patients with Zellweger syndrome. Delayed myelination, 
leukoencephalopathy, and brain atrophy has been 
reported in Zellweger syndrome (17).
Our patients with MLD had white matter involvement 
as periventricular leukodystrophy (a butter-fly pattern) 
without u-fiber involvement. Groeschel et al. reported 
early radiologic findings for this disorder including 
the corpus callosum and central white matter; cerebral, 
pons and cerebellum atrophy were involved as late 
sings. Furthermore, there was an association between 
cerebellar changes and u-fiber involvement (18).
Brain edema and atrophy were seen in our patients with 
MSUD. Abnormal signal in the white matter and signal 
changes in the internal capsule of dorsal limb, cerebral 
hemisphere, and brain stem has been reported in MSUD 
patients (19, 20).
Our phenylketonuria patients had white matter 
involvement. The white matter involvement due to 
intracellular hydrophilic metabolite accumulation has 
been revealed in patients with this disorder ( 21, 22). 
Leukodystrophic changes were found in our patients 
with Krabbe disease. Krabbe patients in the early stage 
of disease have increased dentate/cerebellar white matter 
intensity. Late onset patients, have deep cerebral white 
matter involvement in the posterior corpus callosum 
(23).
Our patients with adrenoleukodystrophy (ALD) had 
leukodystrophic changes mostly in the posterior brain. 
In patients with ALD disorder, asymmetrical occipital 
white matter involvement is reported that is in the 
characteristic appearance of this disorder, as it progresses 
in a rostro-caudal direction (24).
The basal ganglia involvement was seen in our patients 
with Wilson’s disease (Figure 4). Bilateral putaminal 
and thalamic involvement has been noted in Wilson’s 
disease. Of course, radiologic findings may be varied 
from focal thalamic lesions and dilatation of the third 
ventricle (25, 26). Our patients with NCL showed 
generalized brain and cerebellum atrophy in their 
brain MRI. Stroke and brain atrophy were seen in our 
patients with hemocysteinuria. Brain atrophy in patients 
with disorders of amino acid metabolism such as 
hemocysteinuria has frequently been reported (27, 28). 
Our patients with Canavan disease had wide white 
matter involvement with u-fiber involvement. In patients 
with Canavan disease white matter changes with a 
characteristic sub cortical U fibers involvement in the 
Table 2. Practical criteria for detection of neurometabolic patients
History of the same disorder or death in sibling,...(23.5%)
Consanguinity of 
marriage (71.4%)
History 
Behavioral disorder 
(16.9%)
Hypotonocity or 
hypertonocity 
(49.8%)
Microcephaly (25.4%)Macrocephaly (18.8%)Neurological exam
Abnormal skin and 
hair (20.7%)
Dysmorfic feather 
(13.1%)
Hearing impairment (6.6%)
Visual impairment 
(32.9%)
Clinical
Regression (39.4%)Delay (47.4%)Developmental status
Refractory seizures (38%)EEG abnormality (20.8)Current seizure (55%)seizure
Abnormal MRS (11.2%)Abnormal MRI (64%)Neuroimaging
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